Insight Molecular Diagnostics announces proposed public offering
Alpha Vantage · GlobeNewswire · · AI-summarised by FinFlash
Insight Molecular Diagnostics Inc. announced an underwritten public offering of common stock or pre-funded warrants, with the underwriter granted a 15% option for additional shares. Net proceeds are earmarked for working capital and general corporate purposes, including transplantation research and development. The offering is subject to market conditions, with no guarantee of completion, size or terms.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.